The first, highly anticipated randomized trial of adjuvant antiangiogenic therapy in renal cancer was recently reported. Although far from assuring, data from the adjuvant sorafenib or sunitinib for unfavorable renal carcinoma (ASSURE) trial offer a wealth of insights into the disease, treatments, and biological considerations for studies aimed at risk reduction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coppin, C. et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomized trials. BJU Int. 108, 1556–1563 (2011).
Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00559-6 (2016).
Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779–1787 (2006).
Allegra, C. J. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359–364 (2013).
Cameron, D. et al. Adjuvant bevacizumab-containing therapy in triple-negative beast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol. 14, 933–942 (2013).
Wakelee, H. A. et al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. Presented at the 16th World Conference on Lung Cancer; September 6–9; Denver, Colorado. Abstract 1608 (2015).
Corrie, P. G. et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results form a multicenter, open-label, randomized controlled phase study. Lancet Oncol. 15, 620–630 (2014).
Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65 (2010).
Brooks, S. A. et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77–84 (2014).
Rini, B. et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 16, 676–685 (2015).
Acknowledgements
W.K.R. receives support from the National Institutes of Health (grant number K24CA172355).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chism, D., Rathmell, W. Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nat Rev Nephrol 12, 317–318 (2016). https://doi.org/10.1038/nrneph.2016.58
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.58
